Susmed (TSE:4263) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4263 Susmed Inc TSE:4263
75 GF Score
Price 円714.00
GF Value 円849.08
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Susmed Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Susmed is: High Risk: High uncertainty with risk-return tradeoff.

Susmed  (TSE:4263) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Susmed Risk Assessment Related Terms

TSE:4263 vs VEEV, BTSG, HQY: Risk Assessment Comparison

For the Health Information Services subindustry, Susmed's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Susmed Risk Assessment vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Susmed's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Susmed's Risk Assessment falls into.


TSE:4263
75GF Score
Susmed Inc TSE:4263
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円714.00 is trading 15.9% below its estimated GF Value™ of 円849.08. GuruFocus considers Susmed to be Modestly Undervalued.

Key valuation signals for TSE:4263:

  • Risk Assessment:
  • GF Value™: 円849.08 vs. price of 円714.00 (15.9% below fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
75GF Score

Get the complete analysis for TSE:4263

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円714.00
Price
円849.08
GF Value